Powered by
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a pharmaceutical startup focused on developing novel treatments for orphan endocrine diseases, provided a corporate update and reported financial results for the year ended …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-statin cholesterol reducing drug bempedoic acid and an earlier …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) announced that the U.S. Food and Drug Administration (FDA) approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin cholesterol-lowering medicine. Nexletol is indicated as an …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced that Christophe Arbet-Engels has joined the company as Chief Medical …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a “positive opinion” for both its bempedoic …
DETROIT–ID Ventures, the venture capital arm of Invest Detroit, the non-profit that supports business and real estate projects in the city and region, announced that it has been selected by …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), the developer of new endocrine drugs, announced the promotion of Thomas Hoover to the newly created position of chief commercial officer. Hoover joined Millendo …
LANSING–From gamified science learning to empowering youth athletes, entrepreneurs of all kinds joined the Lansing Economic Area Partnership (LEAP) and the greater Lansing community on Nov. 20 for the Hatching …
ANN ARBOR—Phenomics Health Inc., a University of Michigan research spinout that aims to increase the precision of pharmaceuticals by using individual people’s genetic information, announced it acquired patented pharmacometabolomic technology …
ANN ARBOR—Millendo Therapeutics Inc., (Nasdaq: MLND), a clinical-stage pharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, provided a corporate update and reported …